Data Rules! Strategies for Leveraging Data and Defining Value Based Care
Tuesday, April 30, 1:45 PM - 2:15 PM | Room: Mouton
As specialty drugs continue to dominate the market, payers
and manufacturers are developing networks of specialty pharmacies to manage
cost and obtain data. Basic reporting is not enough, and value must be defined.
IHOC, a coalition formed by AmerisourceBergen, is hosting a panel with industry
experts at Asembia Specialty Pharmacy Summit 2019 on Tuesday, April 30 to share how health system specialty
pharmacies are uniquely positioned to provide coordinated care. This
panel explores data needs from various stakeholders and how this impacts
product uptake, access and patient outcomes.
Join these experts, where you will learn:
- How data is driving and defining value-based contracting
- Insights on the challenges and successes of devising metrics that drive outcomes
- How a patient centered-model drives outcomes
VICE PRESIDENT OF STRATEGIC DEVELOPMENT, AMERISOURCEBERGEN
Diane B. Giaquinta, PharmD, FAMCP
Ms. Giaquinta is president of a healthcare consulting company with an emphasis in managed care pharmacy. Her consulting areas of expertise are in product commercialization strategies for managed markets throughout the development cycle and launch, managed care training, customer partnership development, market research and disease management. Her unique perspectives comes from her experience; having held senior management positions in both managed care pharmacy and the pharmaceutical industry, allowing her to understand the requirements and needs of both parties.
DIRECTOR OF NATIONAL ONCOLOGY PATHWAY STRATEGY, EISAI
Ms. Forner leads Eisai's national oncology pathways and value strategy. Her focus is toward the largest oncology delivery systems in the country. These systems are well-balanced between hospital integrated health networks and clinics - the majority of both having specialty pharmacy dispensing capability. Ms. Forner has more than 17 years of pharmaceutical experience with over half of her tenure in critical care institutional sales and oncology.
VICE PRESIDENT, SPECIALTY PHARMACY, UNIVERSITY HOSPITALS HEALTH SYSTEM
Mr. Burgess serves as vice president where his responsibilities include building the best in class outpatient pharmacy operations as new business enterprises. He has a proven and impressive track record in healthcare and business development. His previous experiences include creating business operations that improved service delivery, reduced costs and maximized reimbursement for large health systems.
EXECUTIVE DIRECTOR, BIOSIMILAR ACCESS, BOEHRINGER INGELHEIM
Mr. Koenig is responsible for the commercial development and implementation of market access strategies for biosimilar candidates at Boehringer Ingelheim. He has a diverse background that includes leadership roles in market access, account management, payer marketing and sales management during his 20-plus year career. Previously, he served in a senior role at Biogen where he was responsible for market access strategies in support of the launch of two new hemophilia therapeutics and Alzheimer's disease pipeline products.